Heidelberg, Germany, March 26, 2020 -- Affimed N.V. (Nasdaq: AFMD), a
clinical-stage immuno-oncology company committed to giving patients back
their innate ability to fight cancer, today announced that the company
will participate in the following upcoming virtual investor conferences.
-- Dr. Adi Hoess, Chief Executive Officer, will present at the Solebury
Trout Virtual Global Healthcare Conference Series on Thursday, April 2,
2020 at 9:30 a.m. Eastern Time. The presentation will be webcast live and
available for replay in the investor relations section of Affimed's
website at https://www.affimed.com/investors/webcasts_cp/.
-- Dr. Adi Hoess will conduct virtual one-on-one meetings with institutional
investors at the 2020 Wells Fargo Biotech Corporate Access Day on Tuesday,
April 7, 2020.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company
committed to giving patients back their innate ability to fight cancer.
Affimed's fit-for-purpose ROCK(R) platform allows innate cell engagers
to be designed for specific patient populations. The Company is
developing single and combination therapies to treat hematologic and
solid tumors. For more information, please visit www.affimed.com.
Affimed Investor and Media Contacts
Gregory Gin, Head of Investor Relations
E-Mail: IR@affimed.com
https://www.globenewswire.com/Tracker?data=ECW5WaDjHe7MX7U3h_qzZSct5ijXmGSzkskuoO0CNlV50Q2y_PBgnD7tzoRBuqRt8IR7T9zOc3SBmDLpBHeEdg==
(END) Dow Jones Newswires
March 26, 2020 07:30 ET (11:30 GMT)
